Previous 10 | Next 10 |
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month PR Newswire NEW YORK , April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commer...
2024-04-19 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Let’s just get something straight off the bat – penny stocks to rebound are risky. They’re incredibly treacherous in terms of both short-term downside and longer-term d...
2024-04-08 09:00:06 ET Mark Massaro from BTIG issued a price target of $2.50 for LUCD on 2024-04-08 07:51:00. The adjusted price target was set to $2.50. At the time of the announcement, LUCD was trading at $0.9277. The overall price target consensus is at $3.30 with hig...
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention...
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio tec...
2024-03-26 16:27:08 ET Lucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Conference Call March 26, 2024, 08:30 AM ET Company Participants Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Kyle Mikson - Canaccord Joseph Con...
2024-03-25 17:55:53 ET Read the full article on Seeking Alpha For further details see: Lucid Diagnostics reports preliminary Q4 results
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results PR Newswire Quarterly EsoGuard ® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to d...
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative ...
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference PR Newswire Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophage...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date Veris Health completes MOU with The Ohio State's James Cancer Hospital Con...
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering ...